Widely used:Recently Viewed
Clear All$0.00
$-0.05
(-99.81%)
As on 21-May-2025 16:00EDT
Today’s Range
52 Week Range
Liquidity
Market cap
--
Revenue (TTM)
--
Net Profit (TTM)
--
ROE
--
ROCE
--
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
EV/EBITDA
--
Div. Yield
--
Debt to Equity
--
Book Value
--
EPS
--
Face value
--
Shares outstanding
--
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
DMK Pharmaceuticals Corporation (DMKPQ)
| -- | -- | -- | -- | -98.5 | -92.1 | -77.4 |
|
BSE Sensex*
| 3.5 | 1.9 | 7.5 | 9.5 | 14.2 | 21.2 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage... product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 28, 2024. Read more
Chief Financial Officer
Mr. Seth Abraham Cohen
Chief Restructuring Officer
Mr. Seth Abraham Cohen
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of DMK Pharmaceuticals Corporation (DMKPQ) is $0.00 (NASDAQ) as of 21-May-2025 16:00 EDT. DMK Pharmaceuticals Corporation (DMKPQ) has given a return of -98.48% in the last 3 years.
DMK Pharmaceuticals Corporation (DMKPQ) has a market capitalisation of $ 0 Mln as on 16-May-2025. As per Value Research classification, it is a Small Cap company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the DMK Pharmaceuticals Corporation (DMKPQ) and enter the required number of quantities and click on buy to purchase the shares of DMK Pharmaceuticals Corporation (DMKPQ).
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 28, 2024.
The CEO & director of Mr. Seth Abraham Cohen. is DMK Pharmaceuticals Corporation (DMKPQ), and CFO & Sr. VP is Mr. Seth Abraham Cohen.
There is no promoter pledging in DMK Pharmaceuticals Corporation (DMKPQ).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| DMK Pharmaceuticals Corporation (DMKPQ) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of DMK Pharmaceuticals Corporation (DMKPQ) was $0 Mln.
